US 11840525
Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer
granted A61PA61P35/00
Quick answer
US patent 11840525 (Use of AURKB small-molecule inhibitors for treatment of non-small cell lung cancer) held by NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD. expires Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- NANJING CHINA-AUSTRALIA INSTITUTE OF TRANSLATIONAL MEDICINE CO., LTD.
- Grant date
- Tue Dec 12 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Dec 07 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 1
- CPC classes
- A61P, A61P35/00